MALLINCKRODT ALBUNEX MARKETING TO BEGIN IN EARLY SEPTEMBER
MALLINCKRODT ALBUNEX MARKETING TO BEGIN IN EARLY SEPTEMBER to an initial group of 10 hospitals following FDA clearance of the product Aug. 5. The approval is the agency's first for an ultrasound contrast imaging agent that can be used for detection in the left side of the heart. Albunex was developed by Molecular Biosystems; Mallinckrodt Medical has marketing rights in North and South America.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth